Thermo Fisher Scientific TMO
$694.76 +$17.82 (+2.63%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $694.76 0.00%
Open$669.20
Prev close$676.94
Day range$661.60 – $697.78
Volume2.09M
Market cap$257.42B
P/E (TTM)36.6
Dividend yield0.26%
Earnings
Average move on report day±3.9%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+9.1%
Worst reaction-9.2%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 21 Oct 2026 | Pre Market | ±5.6% | +0.97% | Within range |
| 2026/Q2 | 23 Jul 2026 | Pre Market | ±5.7% | +8.71% | Bigger than priced |
| 2026/Q1 | 23 Apr 2026 | Pre Market | ±4.6% | -9.20% | Bigger than priced |
| 2025/Q4 | 29 Jan 2026 | Pre Market | ±4.2% | -2.61% | Within range |
| 2025/Q3 | 22 Oct 2025 | Pre Market | ±4.4% | +1.65% | Within range |
| 2025/Q2 | 23 Jul 2025 | Pre Market | ±5.2% | +9.14% | Bigger than priced |
| 2025/Q1 | 23 Apr 2025 | Pre Market | ±5.6% | -0.71% | Within range |
| 2024/Q4 | 30 Jan 2025 | Pre Market | ±4.7% | +6.78% | Bigger than priced |
| 2024/Q3 | 23 Oct 2024 | Pre Market | ±4.3% | -1.69% | Within range |
| 2024/Q2 | 24 Jul 2024 | Pre Market | ±4.0% | +4.07% | Bigger than priced |
| 2024/Q1 | 24 Apr 2024 | Pre Market | ±4.4% | +0.49% | Within range |
| 2023/Q4 | 31 Jan 2024 | Pre Market | ±3.8% | -4.96% | Bigger than priced |
| 2023/Q3 | 25 Oct 2023 | Pre Market | ±4.3% | -5.47% | Bigger than priced |
| 2023/Q2 | 26 Jul 2023 | Pre Market | ±3.8% | +0.61% | Within range |
| 2023/Q1 | 26 Apr 2023 | Pre Market | ±4.3% | -2.78% | Within range |
| 2022/Q4 | 1 Feb 2023 | Pre Market | ±4.1% | +2.99% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$12.14B+9.1% YoY
Operating profit$2.46B+18.7% YoY
Net profit$1.73B+6.5% YoY
Diluted EPS$4.64+8.7% YoY
Free cash flow$2.11B+15.1% YoY
Operating cash flow$2.55B
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin41.4%
Operating margin18.7%
Net margin14.9%
Return on equity13.4%
Return on assets6.5%
Return on invested capital8.3%
Current ratio1.81
Liabilities / assets51.9%
Cash & investments$6.06B
Total debt$41.37B
Net cash (debt)-$35.31B
Free cash flow / sales16.0%
No comments yet — be the first to weigh in on TMO.
Sign in to join the discussion.